Gilead’s Twice-Yearly HIV Prevention Injection Shows 85.6% Persistence And Zero HIV Acquisitions in 52-Week Trial
Gilead Sciences, Inc. (NASDAQ:GILD) today announced results from the PURPOSE 5 trial showing significantly higher persistence—defined as consistent and continuous on-time use—among people starting twice-yearly
Gilead tested a new HIV prevention shot given twice a year. In the trial, most people kept using it and nobody got HIV, which shows the medicine works well and people like using it.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.